Prot # SGTP-002:A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE for Reduction of Delayed Graft Function in Recipients of a Donation after Brain Death Kidney Transplant

Project: Research project

Project Details

StatusFinished
Effective start/end date10/16/15 → 10/16/18

Funding

  • CTI Clinical Trial and Consulting Services (Prot # SGTP-002)
  • Prolong Pharmaceuticals, LLC (Prot # SGTP-002)